News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
nmti
Sounds good man. This could turn into a nice one 
|
Followers
|
16
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
296
|
|
Created
|
04/29/08
|
Type
|
Free
|
| Moderators | |||
NMT Medical Announces First-Quarter 2008 Financial Results
Tuesday May 6, 7:30 am ET
For the first quarter of 2008, NMT reported a net loss of approximately $3.9 million, or $0.30 per share. This compares with a net loss of approximately $336,000, or $0.03 per share, for the comparable period in 2007.
27 Wormwood street
Boston, MA 02210-1625
United States - Map
Phone: 617-737-0930
Fax: 617-737-0924
Web Site: http://www.nmtmedical.com
DETAILS
Index Membership: N/A
Sector: Healthcare
Industry: Medical Instruments & Supplies
Full Time Employees: 118
BUSINESS SUMMARY
NMT Medical, Inc., a medical technology company, engages in the design, development, manufacture, and marketing of proprietary implant technologies that allow interventional cardiologists to treat cardiac structural heart disease through minimally invasive, catheter-based procedures.
Technology Overview http://www.nmtmedical.com/technology.aspx?id=206
Its products primarily include CardioSEAL, a cardiac septal repair implant device used for the repair of structural heart disease and intracardiac shunts that result in abnormal blood flow through the chambers of the heart; STARFlex, which incorporates a self-centering system that allows the implant to self-adjust to variations in the anatomy of a septal defect without deforming the septum or interfering with heart valve function; and BioSTAR, a bioabsorbable PFO implant and biological closure technology.
The company also develops BioTREK, which incorporates a unique biosynthetic material that uses the body's own regenerative capability to restore function naturally.
NMT Medical's customers include hospitals, clinics, and other healthcare centers. It markets its product CardioSEAL through its direct sales force to customers in the United States and Canada; and CardioSEAL, STARFlex, and BioSTAR directly in European markets, as well as through selected distributors in the other parts of Europe. The company was founded in 1986 and is headquartered in Boston, Massachusetts.
NMT Medical is currently investigating the potential connection between a common heart defect that allows a right to left shunt or flow of blood through a defect like a patent foramen ovale (PFO) and brain attacks such as embolic stroke, transient ischemic attacks (TIAs) and migraine headaches. A common right to left shunt can allow venous blood, unfiltered and unmanaged by the lungs, to enter the arterial circulation of the brain, possibly triggering a cerebral event or brain attack. More than 27,000 PFOs have been treated globally with NMT's minimally invasive, catheter-based implant technology. NMT Medical was founded in 1986 and is headquartered in Boston, Massachusetts.
Stroke Opportunity
PFO has been implicated as a possible risk factor of embolic stroke and TIA, for which current treatments include lifelong drug therapy or open heart surgery. NMT estimates the worldwide market for stroke- and TIA-related PFO closure procedures at 250,000 annually.
Migraine Opportunity
Medical research suggests that PFO may be a factor in certain migraine headaches. Of the 30 million migraine sufferers in America, those who experience aura and have a PFO may represent up to a 1.5 million patient subset. This represents NMT’s U.S. target market.
KEY EXECUTIVES
Mr. John Ahern , 63
Chief Exec. Officer, Pres
Mr. Richard E. Davis , 49
Chief Financial Officer, Principal Accounting Officer, Exec. VP and Sec.
Mr. Brad Ryno ,
VP of Worldwide Sales
Mr. Geoff Fournie ,
VP of Clinical Devel. for Europe
Shares
12.97 m
Float
12.6 mil
